Glucagon-like peptide-1 (GLP-1) brands Wegovy and Zepbound, along with their counterparts approved for type 2 diabetes — Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro, respectively — have begun to ...
Addiction is yet another area where GLP-1s might be effective. Preliminary evidence looks promising, but questions remain.
Some of what RFK Jr. says about obesity prevention isn't new. But after having coined the catchy MAHA acronym, it’s likely ...
There’s no single GLP-1 diet plan you need to follow. If you’re taking — or thinking about taking — a GLP-1 medication like ...
Berberine, green tea extract and taurine are just some of the ingredients advertised as being able to ‘boost’ GLP-1 levels.
A cross-sectional study of privately insured patients with obesity showed that the use of GLP-1 RAs soared from 2022 to 2023, ...
A doctor, bariatric surgeon and professor say that treatments other than weight-loss drugs are needed to fix the obesity crisis.
The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. The ...
Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.
Millions of NHS patients could wait 12 years for weight-loss drug Mounjaro, which rivals Ozempic and Wegovy. Although the ...
As anti-obesity medications gain popularity, a new concern has also gained traction among researchers: increased food waste. A self-administered online survey sponsored by Ohio State found that 25% of ...
A study finds that anti-obesity medications may help reduce alcohol consumption, with nearly half of participants in weight ...